fbpx
Greg Brozeit

About Greg Brozeit

Greg is the Program Director for the Myeloma Crowd patient education programs. He is based in Northeast Ohio.

On the Verge of Wisdom: Notes from the Myeloma Charlotte Plasma Cell Disorder Congress

“True wisdom is knowing what you do not know.”                                     Attributed to Confucius “We’re missing half the story right now,” according to Dr. Kenneth Anderson of the Dana-Farber Cancer Institute at the Inaugural Plasma Cell Disorder Congress in Charlotte, NC on August 10-11, 2019, “but we’ll repair that.”  His comment summed up the Congress’s presentations—myeloma [...]

Read More

There’s a New Kid In Town: Dr. William Matsui Develops New Multiple Myeloma Research Program in Austin, Texas

“One big thing that differentiates the approach here in Austin compared to my past experience is that clinical care is modeled on a ‘team of providers’ approach—nurse practitioners, social workers, nutritionists, psychologists, fertility specialists, genetic counselors—to individualize treatment.  I think we do a better job of taking care of the entire patient, not just their [...]

Read More

September 11: No Expiration Date for Those Near Ground Zero

More than 17 years after September 11, 2001, the list of casualties from the attack on the Twin Towers continues to grow. Cancers, respiratory conditions and other diseases continue to take their toll on those who breathed in the toxic dust that enveloped lower Manhattan.  When this became too obvious to ignore, the Zadroga Act [...]

Read More

A New Kind of New Year’s Resolution for Multiple Myeloma

Day 12 of Myeloma Giving: From December 10 – 31, the Myeloma Crowd is sharing 12 Days of Myeloma Giving. Please share this post and invite your friends and family to participate. Each day we will share something you can give to lift others. These gifts will save lives, lengthen lives and makes lives happier [...]

Read More

Day 10 of Myeloma Giving: Tell a Friend About HealthTree

Day 10 of Myeloma Giving: Tell a Friend About HealthTree From December 10 – 22, the Myeloma Crowd is sharing 12 Days of Myeloma Giving. Please share this post and invite your friends and family to participate. Each day we will share something you can give to lift others. These gifts will save lives, lengthen [...]

Read More

Day 7 of Myeloma Giving: Check in With a Myeloma Friend

Day 7 of Myeloma Giving: Check in with a Myeloma Friend From December 10 – 21, the Myeloma Crowd is sharing 12 Days of Myeloma Giving. Please share this post and invite your friends and family to participate. Each day we will share something you can give to lift others. These gifts will save lives, [...]

Read More

Day 3 of Myeloma Giving: Share an Article About Myeloma – Here’s What I Learned

Day 3 of Myeloma Giving: Share an article about Multiple Myeloma From December 10 - 21, the Myeloma Crowd is sharing 12 Days of Myeloma Giving. Please share this post and invite your friends and family to participate. Each day we will share something you can give to lift others. These gifts will save lives, [...]

Read More

ASH 2018: Adding Daratumumab to Velcade/Revlimid/Dex Effective for Newly Diagnosed Multiple Myeloma

Patients who combine daratumumab (Dara) with a bortezomib-lenalidomide-low dose dexamethasone (VRd) regimen have deeper, more durable responses to their treatment, experience few significant adverse events and the four drug combination does not affect eligibility for stem cell transplants. Peter Voorhees from the Levine Cancer Institute reported the findings of a phase 2 study in an [...]

Read More

ASH 2018: Ixazomib and Elotuzumab Combos are Promising for High-Risk Smoldering Patients

None of the 50 smoldering myeloma patients with high-risk genetics who took part in a phase 2 clinical trial of early intervention with a combination of elotuzumab, lenalidomide and dexamethasone progressed to active myeloma and monitoring of them is ongoing. Patients who took part in the trial ranged in age from 29-79 and were found [...]

Read More

ASH 2018: Determining Multiple Myeloma Risk and Survival Rates

A need exists to further stratify myeloma patients according to genetic and blood signatures in order to better predict patient survival rates, according to Dr. Dirk Hose (Hoe-zeh), from the University of Heidelberg, Germany, at the annual ASH meeting in San Diego on Sunday, December 2. Hose led off six lectures on possible biological measurements [...]

Read More

New Myeloma Meetups: Education and Support for the African American Myeloma Community

The Myeloma Crowd will expand its new Meetups program to include in-person myeloma patient education meetings called Myeloma Meetups: Education and Support for the African American Myeloma Community. The first two programs will be held in Detroit, MI on Saturday, September 15 and Louisville, KY on Saturday, October 6. The Myeloma Crowd is working with [...]

Read More

FDA Orphan Status for Myeloma T Cell Therapy

The U.S. Food & Drug Adminstration (FDA) granted orphan status to a targeted immunotherapy drug for myeloma called galinpepimut (GPS) on May 9, 2018.  GPS is a vaccine that targets the WT1 antigen which, according to manufacturer SELLAS Life Sciences Group, “is one of the widely expressed cancer antigens” found a variety of cancer [...]

Read More

Staten Island Myeloma Support Group: September 11 Victims Fund Info

If you’re reading this, you know about myeloma. If you’re from the New York City area and spent a lot of time in Lower Manhattan on or after September 11, 2001 and were exposed—or know someone who was—to the dust and smells of the area for a prolonged time and were—or knows someone who [...]

Read More

NCI Awards Grant on Overcoming Myeloma Drug Resistance

The National Cancer Institute (NCI) awarded a $6 million grant to a team of myeloma researchers to study how myeloma treatment can be improved to help patients—especially those with relapsed and refractory disease—overcome drug resistance. Dr. Keith Stewart, the principal investigator, will lead one of three projects together with Dr. Leif Bergsagel, his colleague from [...]

Read More

Myeloma Drug Candidate Gets Breakthrough Status

By: Greg Brozeit GlaxoSmithKline (GSK) announced that an antibody being developed to target BCMA in myeloma received the Food & Drug Administration’s (FDA) “Breakthrough Therapy Designation” on November 2, 2017. The new agent, GSK2857916, was granted similar status by the European Medicines Agency (EMA), the European Union’s counterpart to FDA, in October.  Both designations are [...]

Read More

Will Blood Cancer Gene Therapy Be Affordable?

BY GREG BROZEIT Sticker shock has tempered excitement about the Food & Drug Administration’s (FDA) recent approval of the first gene therapy available for clinical use.  Initial reports indicate the newly approved drug, a single treatment CAR T cell procedure for a rare form of leukemia, will cost as much as $475,000.  Yesterday a New [...]

Read More

Second Blood Cancer Drug Approval in Two Days Confirms Treatment Theory

BY GREG BROZEIT The Food and Drug Administration (FDA) approved a “first drug of its kind to be approved for any cancer” for the second time in two days, on August 31, 2017.  Enasidenib (Idhifa®) treats acute myeloid leukemia (AML) and is based on the emerging science of epigenetics, a theory that focuses on how [...]

Read More

Car T-Cell Research Moves Into Clinical Practice

The Food and Drug Administration (FDA) today approved “the first gene therapy available in the United States,” a chimeric antigen receptor (CAR) T-cell therapy called Kymriah, which will be used to treat acute lymphoblastic leukemia (ALL) in some children and young adults. “This is an exciting development for everyone in the blood cancer community,” said [...]

Read More

Policy and Politics: What Cancer Advocates Must Understand

BY GREG BROZEIT “Public policy” is often a misunderstood concept.  Everyone thinks they know what it means, but few, in my experience, understand what it really is and too often confuse it with politics.  In the cancer world this is counter-productive.  Confusing them in the long term may be deadly. Strictly defined, public policy refers [...]

Read More

High-Risk Multiple Myeloma Patients Benefit from Aggressive Treatment

Dr. Sagar Lonial of Emory University’s Winship Cancer Institute recently discussed his paper on how he treats high-risk myeloma with Dr. Neil Love of Research To Practice: An Integrated Approach to Oncology Education. A big question for physicians, according to Dr. Lonial, was whether their patients “should they get maintenance therapy and what should they [...]

Read More

Don’t Obsess About Cancer Causes

BY GREG BROZEIT Researchers found that two thirds of cancer-causing cell mutations occur because of “bad luck.” Harper’s Magazine Weekly Review, March 28, 2017 That’s a bit of an oversimplification about a recently published paper in Science magazine.  So, if you’re a cancer patient, should this interest you?  Yes and no. Yes if you are intellectually [...]

Read More

Columbus, Ohio Event Leads Way for African American Myeloma Patients

BY GREG BROZEIT “In the audience, I could see and feel memories of my grandparents who had cancer; who were my inspiration to go into medicine.  To speak in a church that was just like the church I went to as a child...it really was coming full circle for me.”  Dr. Craig Emmitt Cole, University of [...]

Read More

ASH 2016: Kicking It Off With CAR T-Cells

BY GREG BROZEIT If it’s the first Saturday of December, it must be the beginning of the annual American Society of Hematology (ASH) meeting.  ASH also has it’s equivalent of pre-season, the Friday Satellite Symposia, the day before its official opening, but in this case, it means something.  Twenty-three sessions of two-to-three hours cover virtually [...]

Read More

Contrarian Civics: Rethinking Coalition Building

BY GREG BROZEIT Medical research funding should be one of our highest national priorities.  Achieving cures for deadly and debilitating diseases can, I believe, become one of the great global civil rights issues of our time. To dramatically increase funding for the National Institutes of Health (NIH), the nation’s engine of medical discovery, I [...]

Read More

Contrarian Civics: How Should Personal Experience Impact Policy?

BY GREG BROZEIT I have worked almost 30 years in various levels of public policy—as an educator, U.S. Senate staffer, policy analyst and grassroots organizer and come to the conclusion, paradoxically, that the greatest strength and weakness of political advocacy is one and the same: personal experience. Personal experience informs opinions and convictions; what [...]

Read More

Nanotechnology: Cancer’s Fantastic Voyage?

BY GREG BROZEIT Progress in science depends on new techniques, new discoveries and new ideas, probably in that order. Sydney Brenner, Nobel Laureate “To see,” the poet Paul Valéry once wrote, “is to forget the name of the things that one sees.”  To see DNA is to forget its name or its chemical formula.  Like [...]

Read More

Clinical Trials Participation: Cancer’s Achilles Heel?

BY GREG BROZEIT If you are a myeloma patient and could help doctors and researchers cut the times to develop effective drugs by half, would you do it?  If you could do so without having to raise millions of dollars, would you do it?  If you answered yes to both of those questions, then learning [...]

Read More

First Myeloma Crowd Round Table Held in Salt Lake City

The Myeloma Crowd launched its Round Tables on High-Risk Disease program in Salt Lake City, UT on Saturday, May 7, 2016.  Host Dr. Rafael Fonseca of Mayo Clinic Scottsdale was joined by Dr. Guido Tricot of the Holden Cancer Center at the University of Iowa and Dr. Djordje Atanackovic of Huntsman Cancer Institute at the [...]

Read More

Sorting Out ICER and CMS Issues

The Myeloma Crowd added its name to a joint letter expressing concerns about the Institute for Clinical and Economic Review’s (ICER) plan to assign an economic “value” to newly approved drugs for refractory myeloma.  According to this broad range of cancer organizations, ICER rules would limit patients’ access by limiting options and impede physicians from [...]

Read More

Americans Support Medical Research Investment

BY GREG BROZEIT A recent poll commissioned by Research!America confirms what advocates have long known: vast, bipartisan majorities of Americans support public investment in medical research. When respondents were asked if their “health has been improved thanks to research over the course of your lifetime,” 74% strongly or somewhat agreed.    Moreover, 90% find it persuasive [...]

Read More

Will Health Insurers Inhibit Medical Progress?

BY GREG BROZEIT Very few patients have noticed an epic struggle taking place among policy wonks, lobbyists, hedge fund managers and economists in the drug and insurance industries.  Some want describe the fight as being about drug pricing and value, but it might actually be about limiting access to newly approved and emerging myeloma [...]

Read More

National Comprehensive Cancer Network (NCCN) Announces Unprecedented Myeloma Guidelines

BY GREG BROZEIT The National Comprehensive Cancer Network (NCCN), an expert panel that develops standard-of-care guidelines for practicing physicians, announced unprecedented recommendations for the treatment of myeloma. Dr. Ken Anderson, chair of the NCCN myeloma panel, told Medscape Medical News that certain patients with smoldering myeloma who “do not have the so-called CRAB features” would [...]

Read More

Ready to Learn More About Myeloma From the Best Doctors Out There? Here’s Your Chance! We’re Hosting A Series Of Round Tables on High-Risk Disease. Salt Lake City Goes First on May 7, Discount Rates Available

The Myeloma Crowd is pleased to announce a new program to help patients and caregivers make better decisions and plans about treatment: Myeloma Crowd Round Tables on High-Risk Disease. These will be day-long patient education meetings featuring top myeloma experts.  They will be held in cities throughout the United States—six are planned in 2016—and focus [...]

Read More

Lucky Man: The Inspiring Story of 24-YEAR Myeloma Survivor Jim Bond

Editor’s note: Until the end of the Muscles for Myeloma challenge on April 30, the Myeloma Crowd will post articles about exercise, updates on the challenge, and profiles of patients who exercise to supplement their treatment plans.  Today’s article profiles Jim Bond, a myeloma patient from Shaker Heights, Ohio, who explains how exercise has been [...]

Read More

Opposition Research: Uncomfortable Truths Cancer Advocates Must Confront

BY GREG BROZEIT Nobody likes negative campaigns, but no matter how much people complain about them, they tend to influence large numbers of voters; low-information voters, I would argue. Negative campaigns are built on opposition research, a cottage industry few understand.  When I worked for a congressional campaign in 1989, I conducted opposition research on [...]

Read More

NIH Gets $2 Billion Increase: A Time to Celebrate? Or for Resolve?

BY GREG BROZEIT Funding for the National Institutes of Health (NIH) increased by $2 billion in the federal government spending bill signed into law by President Obama on December 15, 2015. Most cancer and disease advocates praised the NIH increase, some characterizing it as a “HUGE WIN.” NIH Director Francis Collins stated that this was [...]

Read More

Measured Optimism for Myeloma: Lessons from ASH 2015

BY GREG BROZEIT Thanksgiving kicks off the holiday season for most Americans. But for me, it begins with the annual meeting of the American Society of Hematology (ASH) which is always held in the beginning of December. I attended my first ASH meeting in 1998 when the news of about thalidomide, the first new drug [...]

Read More

MCRI Crowdsourcing: Carpe Diem for Myeloma?

Carpe Diem. Can we seize the day to create revolutionary myeloma treatments? MCRI has selected two research projects, focusing on CAR T cell engineering and T cell immunotherapy, which hold huge promise for high-risk myeloma and all cancer research. It’s time to get involved to make this vision a reality. You and other members [...]

Read More

MCRI: Patient-Driven Promise On Finding Cures & Treatments

BY GREG BROZEIT Spring is the season of planting in hope and anticipation of rewarding harvests. So it was fitting that the Myeloma Crowd Radio interviews with the ten finalists of the Myeloma Crowd Research Initiative (MCRI) took place in spring. To understand the potential these seeds hold, take some time to listen (and re-listen) [...]

Read More

Trickle Up: Unlocking the Potential of Cancer Research?

BY GREG BROZEIT “More than nearly any other form of cancer, multiple myeloma…epitomizes the impact of ... newly discovered targeted therapies.” Siddhartha Mukherjee, The Emperor of All Maladies: A Biography of Cancer “Trickle down” is not just a discredited economic theory. It was also an unspoken method of prioritizing cancer research funding for much of the [...]

Read More